A prospective study of hepatitis B vaccination - a comparison of responders versus nonresponders.

Hdl Handle:
http://hdl.handle.net/10147/207140
Title:
A prospective study of hepatitis B vaccination - a comparison of responders versus nonresponders.
Authors:
Brown, Catherine M; Donlon, Sheila; O'Kelly, Patrick; Casey, Anne Marie; Collier, Cathal; Conlon, Peter J; Walshe, John J
Affiliation:
Department of Nephrology and Transplantation, Beaumont Hospital, Dublin, Ireland., catherinebrownis@gmail.com
Citation:
Ren Fail. 2011;33(3):276-9.
Journal:
Renal failure
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207140
DOI:
10.3109/0886022X.2011.559300
PubMed ID:
21401350
Abstract:
Herein we present one of the largest single-center reports of the response of hemodialysis patients to a two-vaccine hepatitis B virus vaccination protocol in a European dialysis population. A hepatitis B recombinant DNA vaccine, HBvaxPRO, was given at a dose of 40 microg intramuscularly using a four-dose schedule at 0, 1, 2, and 12 months. Responses were (1) a titer >100 mIU/mL = patient immune, (2) a titer level 10-99 mIU/mL = give a booster dose and recheck level 2 months later, and (3) 0 </= 10 mIU/mL = repeat vaccination course using a different vaccine, Engerix-B. We compared responder groups in terms of titer levels for each vaccine and variables including age, gender, serum albumin, parathyroid hormone (PTH), calcium, phosphate, hemoglobin, years on dialysis, and type of dialysis access. Of the 176 patients who received the first vaccine course, 71 patients achieved immunity, that is, 40% uptake for the first vaccine. Of the 105 who failed, 72 received the second vaccine with 46 responders, that is, 64% uptake for the second vaccine. Overall, 143 of the 176 patients who entered the vaccination program completed the protocol with 117 achieving immunity, representing an 82% success rate. The only variable overall to show significance in achieving seroconversion was serum albumin (p = 0.03). Using a two-vaccine protocol, hepatitis B vaccination response was high in our population of end-stage renal disease patients.
Language:
eng
MeSH:
Aged; Female; Hepatitis B/immunology/prevention & control; Hepatitis B Vaccines/administration & dosage/*immunology; Humans; Kidney Failure, Chronic/*immunology; Male; Middle Aged; Prospective Studies; Serologic Tests
ISSN:
1525-6049 (Electronic); 0886-022X (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorBrown, Catherine Men_GB
dc.contributor.authorDonlon, Sheilaen_GB
dc.contributor.authorO'Kelly, Patricken_GB
dc.contributor.authorCasey, Anne Marieen_GB
dc.contributor.authorCollier, Cathalen_GB
dc.contributor.authorConlon, Peter Jen_GB
dc.contributor.authorWalshe, John Jen_GB
dc.date.accessioned2012-02-01T10:00:12Z-
dc.date.available2012-02-01T10:00:12Z-
dc.date.issued2012-02-01T10:00:12Z-
dc.identifier.citationRen Fail. 2011;33(3):276-9.en_GB
dc.identifier.issn1525-6049 (Electronic)en_GB
dc.identifier.issn0886-022X (Linking)en_GB
dc.identifier.pmid21401350en_GB
dc.identifier.doi10.3109/0886022X.2011.559300en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207140-
dc.description.abstractHerein we present one of the largest single-center reports of the response of hemodialysis patients to a two-vaccine hepatitis B virus vaccination protocol in a European dialysis population. A hepatitis B recombinant DNA vaccine, HBvaxPRO, was given at a dose of 40 microg intramuscularly using a four-dose schedule at 0, 1, 2, and 12 months. Responses were (1) a titer >100 mIU/mL = patient immune, (2) a titer level 10-99 mIU/mL = give a booster dose and recheck level 2 months later, and (3) 0 </= 10 mIU/mL = repeat vaccination course using a different vaccine, Engerix-B. We compared responder groups in terms of titer levels for each vaccine and variables including age, gender, serum albumin, parathyroid hormone (PTH), calcium, phosphate, hemoglobin, years on dialysis, and type of dialysis access. Of the 176 patients who received the first vaccine course, 71 patients achieved immunity, that is, 40% uptake for the first vaccine. Of the 105 who failed, 72 received the second vaccine with 46 responders, that is, 64% uptake for the second vaccine. Overall, 143 of the 176 patients who entered the vaccination program completed the protocol with 117 achieving immunity, representing an 82% success rate. The only variable overall to show significance in achieving seroconversion was serum albumin (p = 0.03). Using a two-vaccine protocol, hepatitis B vaccination response was high in our population of end-stage renal disease patients.en_GB
dc.language.isoengen_GB
dc.subject.meshAgeden_GB
dc.subject.meshFemaleen_GB
dc.subject.meshHepatitis B/immunology/prevention & controlen_GB
dc.subject.meshHepatitis B Vaccines/administration & dosage/*immunologyen_GB
dc.subject.meshHumansen_GB
dc.subject.meshKidney Failure, Chronic/*immunologyen_GB
dc.subject.meshMaleen_GB
dc.subject.meshMiddle Ageden_GB
dc.subject.meshProspective Studiesen_GB
dc.subject.meshSerologic Testsen_GB
dc.titleA prospective study of hepatitis B vaccination - a comparison of responders versus nonresponders.en_GB
dc.contributor.departmentDepartment of Nephrology and Transplantation, Beaumont Hospital, Dublin, Ireland., catherinebrownis@gmail.comen_GB
dc.identifier.journalRenal failureen_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.